International Journal of Clinical Research

Objective To understand the prevalence of drug resistance in HIV-infected and AIDS patients in this region before initial antiviral therapy, that is, transmissible drug resistance, and to provide reference for newly infected HIV patients when choosing antiviral therapy or failure in antiviral therapy. Methods Baseline HIV-1 drug resistance detection was performed by PCR-electrophoresis sequencing in 120 blood samples of HIV/AIDS from the Third Peoples Hospital of Linfen from 2021 to 2022. The mutation sites and drug resistance categories of the 120 samples were analyzed according to the genotypic drug resistance test reports. Results Among the 120 cases, 19 cases (15.8%) showed the phenomenon of transmissible drug resistance, especially the mutation of K103N, V106I and M184V. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) were resistant in 17 patients (89.47%). Two patients were resistant to both nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). Protease inhibitor (PIs) drug resistant in 1 person, and potential drug resistant (P). Compared with 18 cases of acquired drug resistance in the same period, the acquired drug resistance had more mutation sites, higher drug resistance rate and higher degree of drug resistance. Conclusion At present, there is a high proportion of drug resistance before initial antiviral treatment, especially the spread of drug resistance of NNRTIs, and the effective viral inhibition rate and treatment failure of antiviral drugs are bound to be greatly affected. Only by paying attention to the epidemic situation of drug resistance, actively carrying out the spread of drug resistance detection, and selecting sensitive drugs for treatment can effective treatment be achieved. These resistance mutations are closely related to the efficacy of antiviral therapy and virus transmission. This study provides an important basis for the formulation of effective antiviral treatment and prevention and control strategies.

HIV-1; Gene sequencing; Mutation site; Transmissible drug resistance